endocannabinoid system has been shown to attenuate inflammatory events such as the differentiation of myelin-specific T cells, the production of pro-inflammatory mediators (tumor necrosis factor (TNF)-α, nitric oxide (NO), interleukin (IL)-1β, IL-2 and IL-6 and the activation and infiltration of microglia, leading to a slowed progression of inflammatory disorders (Croxford & Miller, 2003; Ortega-Gutierrez et al., 2005). CB1 activation has been shown to be effective in limiting cell death following excitotoxic lesions, while CB2 receptor is involved in decreasing inflammatory immune cell response to disease (Scotter et al., 2010). AM404, an endocannabinoid modulator, normalizes chronic constriction injury in NO activity (Costa et al., 2006; La Rana et al., 2006), cyclooxygenase-2 activity (La Rana et al., 2006), cytokine levels such as TNF-α, NF-κB levels and IL-10 (Costa et al., 2006). In the USA, since 1996, 14 states (Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, and Washington) have amended their state laws to allow cannabis, prescribed by licensed physicians, to be used, by people with debilitating medical conditions (Hoffmann & Weber, 2010; MacDonald, 2009). Finally, the National Institutes of Health, the Institute of Medicine and the American College of Physicians have renewed their
